Using immunotherapy before surgery for liver cancer
Preoperative immunotherapy in Hepatocellular Carcinoma
['FUNDING_R21'] · EMORY UNIVERSITY · NIH-10852872
This study is looking at how a special drug called regorafenib can help boost the effectiveness of an immune therapy for people with liver cancer before they have surgery, with the goal of reducing the chances of the cancer coming back afterward.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10852872 on ClinicalTrials.gov |
What this research studies
This research investigates the use of immunotherapy in patients with hepatocellular carcinoma (HCC) before surgical removal of the tumor. It focuses on understanding how a specific drug, regorafenib, can enhance the effectiveness of an anti-PD-L1 antibody therapy by targeting immune cells that contribute to tumor growth and recurrence. The study aims to improve patient outcomes by reducing the chances of cancer returning after surgery through a combination of therapies that address immune resistance. Patients will be monitored for changes in their immune response and tumor characteristics during the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with high-risk hepatocellular carcinoma, particularly those with large tumors, multifocal disease, or vascular invasion.
Not a fit: Patients with early-stage hepatocellular carcinoma or those who are not surgical candidates may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the recurrence of liver cancer after surgery, improving survival rates for patients.
How similar studies have performed: Previous research has shown promising results with immunotherapy approaches in other cancers, suggesting potential for success in this novel application for liver cancer.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LESINSKI, GREGORY B. — EMORY UNIVERSITY
- Study coordinator: LESINSKI, GREGORY B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.